white-paper
Good Manufacturing Practices (GMP) require that manufacturers demonstrate that they have cleared drug substances of residual HCPs to the lowest level possible prior to releasing their drug products. The methodologies for meeting this challenge are changing rapidly as new instrumentation and techniques are becoming available to laboratories. The following paper outlines the latest developments, focusing on emerging best practices.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.